Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J.

Clin Cancer Res. 2019 Apr 29. doi: 10.1158/1078-0432.CCR-18-4024. [Epub ahead of print]

PMID:
31036541
2.

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.

Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI.

Cancer Discov. 2019 Jun;9(6):722-737. doi: 10.1158/2159-8290.CD-18-1218. Epub 2019 Apr 23.

PMID:
31015319
3.

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.

Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.

PMID:
30530501
4.

BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.

van de Ven M, Liu X, van der Burg E, Klarenbeek S, Alexi X, Zwart W, Dijcks F, Bouwman P, Jonkers J.

J Pathol. 2018 Sep;246(1):41-53. doi: 10.1002/path.5105. Epub 2018 Jul 4.

PMID:
29877575
5.

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.

Tacconi EM, Lai X, Folio C, Porru M, Zonderland G, Badie S, Michl J, Sechi I, Rogier M, Matía García V, Batra AS, Rueda OM, Bouwman P, Jonkers J, Ryan A, Reina-San-Martin B, Hui J, Tang N, Bruna A, Biroccio A, Tarsounas M.

EMBO Mol Med. 2017 Oct;9(10):1398-1414. doi: 10.15252/emmm.201607446.

6.

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.

Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM.

Nat Commun. 2017 Jul 17;8:15981. doi: 10.1038/ncomms15981.

7.

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.

J Pathol. 2017 Mar;241(4):511-521. doi: 10.1002/path.4857. Epub 2017 Jan 23.

PMID:
27943283
8.

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.

J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

9.

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N.

Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186.

10.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

11.

BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.

Badie S, Carlos AR, Folio C, Okamoto K, Bouwman P, Jonkers J, Tarsounas M.

EMBO J. 2015 Mar 12;34(6):828. doi: 10.15252/embj.201570610. No abstract available.

12.

BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.

Badie S, Carlos AR, Folio C, Okamoto K, Bouwman P, Jonkers J, Tarsounas M.

EMBO J. 2015 Feb 3;34(3):410-24. doi: 10.15252/embj.201488947. Epub 2015 Jan 12. Erratum in: EMBO J. 2015 Mar 12;34(6):828.

13.

Suppression of BRCA1 sensitizes cells to proteasome inhibitors.

Gu Y, Bouwman P, Greco D, Saarela J, Yadav B, Jonkers J, Kuznetsov SG.

Cell Death Dis. 2014 Dec 18;5:e1580. doi: 10.1038/cddis.2014.537.

14.

Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells.

Pickholtz I, Saadyan S, Keshet GI, Wang VS, Cohen R, Bouwman P, Jonkers J, Byers SW, Papa MZ, Yarden RI.

Oncotarget. 2014 Dec 15;5(23):11827-46.

15.

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Bouwman P, Jonkers J.

Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22. Review.

16.

ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets.

Carlos AR, Escandell JM, Kotsantis P, Suwaki N, Bouwman P, Badie S, Folio C, Benitez J, Gomez-Lopez G, Pisano DG, Jonkers J, Tarsounas M.

Nat Commun. 2013;4:2697. doi: 10.1038/ncomms3697.

PMID:
24162189
17.

A high-throughput functional complementation assay for classification of BRCA1 missense variants.

Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J.

Cancer Discov. 2013 Oct;3(10):1142-55. doi: 10.1158/2159-8290.CD-13-0094. Epub 2013 Jul 18.

18.

BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.

Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, Bouwman P, Cescon DW, Elia AJ, Winterton-Perks Z, Cruickshank J, Brenner D, Tseng A, Musgrave M, Berman HK, Khokha R, Jonkers J, Mak TW, Gauthier ML.

J Exp Med. 2013 Jul 29;210(8):1529-44. doi: 10.1084/jem.20121337. Epub 2013 Jul 15.

19.

Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.

Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.

Proc Natl Acad Sci U S A. 2013 May 21;110(21):8632-7. doi: 10.1073/pnas.1305362110. Epub 2013 May 8.

20.

BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny.

Sotiropoulou PA, Karambelas AE, Debaugnies M, Candi A, Bouwman P, Moers V, Revenco T, Rocha AS, Sekiguchi K, Jonkers J, Blanpain C.

Genes Dev. 2013 Jan 1;27(1):39-51. doi: 10.1101/gad.206573.112. Epub 2012 Dec 27.

21.

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Bouwman P, Jonkers J.

Nat Rev Cancer. 2012 Sep;12(9):587-98. doi: 10.1038/nrc3342. Review.

PMID:
22918414
22.

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J.

Cancer Cell. 2011 Dec 13;20(6):797-809. doi: 10.1016/j.ccr.2011.11.014.

23.

Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression.

Bouwman P, Drost R, Klijn C, Pieterse M, van der Gulden H, Song JY, Szuhai K, Jonkers J.

J Pathol. 2011 May;224(1):10-21. doi: 10.1002/path.2861. Epub 2011 Mar 14.

PMID:
21404276
24.

BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.

Badie S, Escandell JM, Bouwman P, Carlos AR, Thanasoula M, Gallardo MM, Suram A, Jaco I, Benitez J, Herbig U, Blasco MA, Jonkers J, Tarsounas M.

Nat Struct Mol Biol. 2010 Dec;17(12):1461-9. doi: 10.1038/nsmb.1943. Epub 2010 Nov 14.

25.

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J.

Nat Struct Mol Biol. 2010 Jun;17(6):688-95. doi: 10.1038/nsmb.1831. Epub 2010 May 9.

26.

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser P, Adams DJ, Wade-Martins R, Bouwman P, Jonkers J.

Clin Cancer Res. 2010 Jan 1;16(1):99-108. doi: 10.1158/1078-0432.CCR-09-2434. Epub 2009 Dec 15.

27.

Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.

Bouwman P, Jonkers J.

Cell Cycle. 2008 Sep 1;7(17):2647-53. Epub 2008 Sep 8. Review.

PMID:
18728395
28.

Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.

van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J.

Mol Cell Biol. 2006 Jul;26(13):5015-22.

29.

Defective paracrine signalling by TGFbeta in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia.

Carvalho RL, Jonker L, Goumans MJ, Larsson J, Bouwman P, Karlsson S, Dijke PT, Arthur HM, Mummery CL.

Development. 2004 Dec;131(24):6237-47. Epub 2004 Nov 17.

30.

Impaired hematopoiesis in mice lacking the transcription factor Sp3.

Van Loo PF, Bouwman P, Ling KW, Middendorp S, Suske G, Grosveld F, Dzierzak E, Philipsen S, Hendriks RW.

Blood. 2003 Aug 1;102(3):858-66. Epub 2003 Apr 3.

31.

Regulation of the activity of Sp1-related transcription factors.

Bouwman P, Philipsen S.

Mol Cell Endocrinol. 2002 Sep 30;195(1-2):27-38. Review.

PMID:
12354670
32.

Complex phenotype of mice homozygous for a null mutation in the Sp4 transcription factor gene.

Göllner H, Bouwman P, Mangold M, Karis A, Braun H, Rohner I, Del Rey A, Besedovsky HO, Meinhardt A, van den Broek M, Cutforth T, Grosveld F, Philipsen S, Suske G.

Genes Cells. 2001 Aug;6(8):689-97.

33.

Transcription factor Sp3 is essential for post-natal survival and late tooth development.

Bouwman P, Göllner H, Elsässer HP, Eckhoff G, Karis A, Grosveld F, Philipsen S, Suske G.

EMBO J. 2000 Feb 15;19(4):655-61.

34.

Supplemental Content

Loading ...
Support Center